Heart Failure
This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial
- PDF / 9,891,529 Bytes
- 574 Pages / 439.42 x 683.15 pts Page_size
- 8 Downloads / 208 Views
Johann Bauersachs Javed Butler Peter Sandner Editors
Heart Failure
Handbook of Experimental Pharmacology
Volume 243 Editor-in-Chief J.E. Barrett, Philadelphia
Editorial Board V. Flockerzi, Homburg M.A. Frohman, Stony Brook, NY P. Geppetti, Florence F.B. Hofmann, Mu¨nchen M.C. Michel, Mainz C.P. Page, London W. Rosenthal, Jena K. Wang, Beijing
More information about this series at http://www.springer.com/series/164
Johann Bauersachs • Javed Butler Peter Sandner Editors
Heart Failure
Editors Johann Bauersachs Klinik für Kardiologie und Angiologie Medizinische Hochschule Hannover Hannover, Niedersachsen Germany
Javed Butler Heart Institute Stony Brook University Stony Brook, New York USA
Peter Sandner Bayer Aktiengesellschaft Drug Discovery – Cardiovascular Research Heart and Vascular Diseases Wuppertal, Nordrhein Westfalen Germany
ISSN 0171-2004 ISSN 1865-0325 (electronic) Handbook of Experimental Pharmacology ISBN 978-3-319-59658-7 ISBN 978-3-319-59659-4 (eBook) DOI 10.1007/978-3-319-59659-4 Library of Congress Control Number: 2017942786 # Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Heart Failure and Heart Failure Drug Therapy: Preface
Chronic heart failure (HF) remains a worsening global problem and represents the end sequelae of a variety of cardiovascular (CV) diseases. With the worldwide aging of the population and an increasing burden of comorbidities, it is projected that the increasing prevalence of HF will pose an even greater challenge to future healthcare systems than at present. Thus, identifying effective pharmacologic therapies for patients with HF, to reduce the burde
Data Loading...
